Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03821857 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Sex-Specific Effects of Endocrine Disruption on Aging and Alzheimer's Disease

Study acronym: SEED-AD
StatusRecruiting
PhasePhase 4
Started2019-06-27
View on ClinicalTrials.gov ↗

Amendment history

2025-11-19
Active, Not Recruiting→Recruiting Study Identification, Study Status, Oversight, Study Description, Study Design, Eligibility, Contacts/Locations v10
Trial statusActive, Not Recruiting→Recruiting
Enrollment target200→614
Study sites1→2
Eligibility criteria+370 characters
Mayo Clinic Rochester- Inclusion Criteria: Women who livedpreviously participated in Olmstedthis County, Minnesota between 1988 and 2007study Currently aged 5560 years and older More than six months post chemotherapy or major surgery requiring general anesthesia Willing and able to sign informed consent Exclusion Criteria: Not able to read and speak English In hospice Claustrophobic If undergoing Tau imaging, cannot have QT Prolongation Mayo Clinic Jacksonville- Inclusion C [...] More than six months post chemotherapy or major surgery requ [...]
Study description+505 characters
The proposed project will enroll 200a total of 614 women. Mayo Clinic Rochester Participants: Each women will have one2-3 clinic visitvisits consisting of cognitive testing, tests of physical function [...] on PET as a marker of neurofibrillary tangles using AV-1451. All participants will have previously participated and will return by invitation only. Mayo Clinic Jacksonville Participant: Only African American Women will be enrolled at this site. Each women will have 1-3 clinic visits consisting of physical function testing and neuroimaging, which includes str [...]
2025-06-18
Study Status, Oversight v9
Primary completion date2025-05→2030-05
Completion date2025-05→2030-05
2024-06-06
Study Status, References v8
Primary completion date2024-05→2025-05
Completion date2024-05→2025-05
2023-06-05
Recruiting→Active, Not Recruiting Study Status, Contacts/Locations v7
Trial statusRecruiting→Active, Not Recruiting
Primary completion date2023-05→2024-05
Completion date2023-05→2024-05
Study sitesdetails revised at 1 of 1 site
2022-07-07
Study Status, Sponsor/Collaborators, Arms and Interventions, Contacts/Locations v6
Primary completion date2023-03→2023-05
Interventions18-F-Flortaucipir (Diagnostic Test)→18-F-Flortaucipir (Drug)
Study sitescontacts updated at 1 of 1 site
Show 5 earlier versions
2021-10-14
Study Identification, Study Status, Sponsor/Collaborators v5
Collaborators+33 characters
National Institute on Aging (NIA)
2020-10-14
Study Status v4
Re-verified, no change to tracked fields
2019-10-10
Study Status v3
Start dateestimated 2019-08→confirmed 2019-06-27
2019-08-28
Not Yet Recruiting→Recruiting Study Status, Sponsor/Collaborators, Contacts/Locations v2
Trial statusNot Yet Recruiting→Recruiting
Start date2019-06→2019-08
2019-04-22
Study Status, IPDSharing, References v1
Start date2019-03→2019-06
2019-01-28
Original filing
Mayo Clinic
1,015 trials monitored
See 115 trials at risk
Alzheimer's Disease
1,140 trials monitored
See 62 trials at risk
The researchers are trying to determine whether ovarian hormones are associated with aging processes and with the risk of developing Alzheimer's disease in women.
Trial Details
NCT Number NCT03821857
Lead Sponsor Mayo Clinic
Collaborators: National Institute on Aging (NIA)
Conditions Alzheimer Disease
Enrollment 614 participants
Start Date 2019-06-27
Primary Completion 2030-05 (estimated)
Study Completion 2030-05 (estimated)
Updated on ClinicalTrials.gov 2025-11-24